MEDI 4920

Drug Profile

MEDI 4920

Alternative Names: MEDI4920

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator MedImmune
  • Class Biological proteins
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 18 May 2016 MedImmune completes a phase I trial in healthy volunteers in United Kingdom (NCT02151110)
  • 01 May 2016 Phase-I clinical trials in Rheumatoid arthritis in USA (IV) (NCT02780388)
  • 30 Jun 2014 Phase-I clinical trials in Sjogren's syndrome (In volunteers) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top